So-called "rAAVs" (recombinant adeno-associated viruses) have great potential for treating or curing diseases caused by missing or defective genes: Head of Laboratory Astrid Dürauer (pictured) and her team, supported by commercial partner Boehringer Ingelheim International GmbH, work on laying important foundations in this field to contribute to a future in which these promising medications can be made available to patients efficiently and in sufficient quantities!
Further information on the CD Laboratory
Press release (BOKU Wien)
New CD Laboratory as foundation for future therapies
07.03.2024: The Christian Doppler Laboratory for Knowledge-based Production of Gene Therapy Vectors opens at BOKU Wien.
CDG-News